Jason Karlawish
speaker
1,378 appearances
5 recordings
1 series
first heard Feb 2021
last heard Dec 2023
Jason Karlawish’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Pow is very compelling.
But again, measures like neurofilament light, GFAP, uh, et cetera, are very exciting measures that could allow you to say, yeah, you've got amyloid, but you've got no neurofilament, no GFAP, things look really quiet versus you've got amyloid and you've got evidence that there's active neurodegeneration going on.
I I see this as our future and we need to get ready for it.
So but may have a lot to do with brains not working well.
And two cheers for M R I Roland.
Don't forget the value of M R I.
Thanks a lot, Eric.
Thanks a lot, Alan.
Great to be back.
Alex and Eric.
Thanks so much for having me on.
Oh, I plan to prescribe lecanomab and denanomab.
Well lecanomab I because it's FDA approved, assuming Dananomab is FDA approved, I will be a prescriber.
Um and I do think geriatricians need to e as individuals make that decision uh largely based on their comfort with um the diagnostics um and the specifics of the therapeutics.
Um if anyone's wondering, oh wait a minute, what about add to Kennbat?
My answer to that is
Adequantema was just a failure of regulatory science.
Um it wasn't about the drug itself, it was about the decision.
And the drug.
It's quite possible actually Adecanomab is as effective as Lacanomab and Nanomab, but we just don't know that.
Showing 181–200 of 1,378 · page 10 of 69
← Previous
Next →